Evidence map›Paper›PMID 39096178›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024

Plasmonic nanophotothermal therapy: Destruction of 500 mm

Sabrina Pesnel, Antoine Bertolotti, Sébastien Duquenne, Hassan Zahouani, Laurent Mortier, Jean-Luc Perrot, Anne-Laure Morel

Abstract read
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Plasmonic nanophotothermal therapy: Destruction of 500 mmSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sabrina PesnelTORSKAL, Sainte-Clotilde, Réunion, France.ORCID https://orcid.org/0000-0001-7839-4394
Antoine BertolottiCICEC-INSERM1410, Service de Maladies-Infectieuses et Dermatologie, CHU Réunion, Saint-Pierre Cedex, Réunion, France.
Sébastien DuquenneSELARL de pathologie, Saint-Pierre Cedex, Réunion, France.
Hassan ZahouaniEcole Centrale de Lyon, LTDS - TMM, Ecully Cedex, France.
Laurent MortierCHRU Lille, Service de Dermatologie, Hôpital Huriez, Lille, France.
Jean-Luc PerrotCHU Saint Etienne, Service de dermatologie, Hôpital Nord, Lille, France.
Anne-Laure MorelTORSKAL, Sainte-Clotilde, Réunion, France.

Funding

European Regional Development FundMinistère de l'Education Nationale, de l'Enseignement Superieur et de la RechercheRegional council of Reunion Island
6 · The paper itself

Abstract

significanceMultilesional basal cell carcinoma (BCC) are spread on sun exposed skin areas, including arms, face and back. The first-line treatment remains the surgical resection or Mohs surgery. Despite its high complexity, Mohs surgery is well practiced in USA and Germany and presents very good results both in esthetic and in carcinology point of view. Large lesions more than 2 cm remain challenging to remove by topical cream used in photodynamic therapy (PDT). If these larger lesions are not treated in less than 1 month, they could grow deeply in the skin, thus enhancing the risk of reoccurrence and the severity of the disease. Despite this model herein studied, that is non melanoma skin cancer is a good prognostic cancer, the therapy aims to be applied to more aggressive melanoma skin cancers.

aimTotal regression of large cutaneous lesions less than 1 month with no reoccurrence. APPROACH: Tumor induction on murine model bearing a 500 mm

resultsGold nanoparticles alone or the NIR laser alone did not induce the tumor regression. The combination of laser and nanoparticles called plasmonic nanophotothermal therapy induced apoptosis. Derma and hypoderm do not show any visible gold nanoparticles and demonstrated a good cicatrization process.

conclusionPlasmonic nanophotothermal therapy using two doses of gold nanoparticles was the only protocol that proved its efficacy on large lesions in 14 days, that is 500 mm

Indexed as

Basal Cell CarcinomaGoldMetal NanoparticlesPhotothermal TherapySkin NeoplasmsAnimalsCell Line, TumorCombined Modality TherapyFemaleHumansMicePhotochemotherapyGoldbasal cell carcinomagold nanoparticleshyperthermiaNIR Laserphototherapy

Identifiers

PMID39096178
PMCPMC11297533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.